You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Baxter

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Details for Patent: RE46375

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE46375
Title:6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Abstract: A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): ##STR00001## wherein R.sup.1 and R.sup.2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R.sup.3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R.sup.4 is hydrogen or lower alkyl, R.sup.5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically .[.acceptably.]. .Iadd.acceptable .Iaddend.salt, or a solvate thereof is provided.
Inventor(s): Inagaki; Masanao (Toyonaka, JP), Hara; Shin-ichiro (Toyonaka, JP), Haga; Nobuhiro (Osaka, JP), Tamura; Yoshinori (Toyonaka, JP), Goto; Yoshihisa (Amagasaki, JP), Hasegawa; Tsuyoshi (Toyonaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP)
Application Number:15/064,538
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Delivery; Dosage form;

Drugs Protected by US Patent RE46375

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bdsi SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF OPIOID-INDUCED CONSTIPATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE46375

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/JP2006/310231May 23, 2006

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
McKesson
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.